Safety and Efficacy of Low-Level Laser Therapy in Autoimmune Thyroiditis: Long-Term Follow-Up Study. (4th November 2018)

• Record Type: Journal Article
• Authors: Höfling, Danilo Bianchini; Chavantes, Maria Cristina; Buchpiguel, Carlos Alberto; Cerri, Giovanni Guido; Marui, Suemi; Carneiro, Paulo Campos; Chammas, Maria Cristina
• Other Names: Corbetta Sabrina Academic Editor.
• Is Part Of: International journal of endocrinology. Volume 2018(2018)
• Publication Date: 2018-11-04
• Subjects: Endocrinology -- Periodicals; Endocrinology; Endocrinology -- Periodicals; Endocrine System Diseases -- Periodicals; Periodicals; 616.4
• DOI: 10.1155/2018/8387530
• Languages: English
• ISSNs: 1687-8337

Abstract

Abstract : Introduction . A randomized clinical trial (RCT) was performed to evaluate the efficacy of low-level laser therapy (LLLT) for hypothyroidism induced by chronic autoimmune thyroiditis (CAT). Objective . The objective was to assess the safety and actions of LLLT 6 years after completion of the RCT. Materials and Methods . Forty-three participants were invited to participate in this study 6 years after completion of the RCT. Twenty-five were subjected to LLLT (group L), and 18 were subjected to placebo (group P). Primary outcome measure: frequency of thyroid nodules, which were subjected to fine-needle aspiration biopsy. Secondary outcome measures: dose of levothyroxine required to treat hypothyroidism, thyroid peroxidase antibodies (anti-TPO), and anti-thyroglobulin antibodies (anti-Tg). Results . In group L, a nodule was observed in three patients, who all had a Bethesda II classification. In group P, a nodule was also observed in three patients, with two classified as Bethesda II and one as Bethesda III. The levothyroxine dose required by group L was significantly lower than that required by group P (P = 0.002 ). The anti-TPO and anti-Tg levels did not differ between the groups. Conclusion . LLLT, by the methods described, has been shown to be safe for the treatment of hypothyroidism resulting from CAT. This trial is registered with ClinicalTrials.gov Identifier:NCT02240563 .